Michelle van der Vlugt-Daane
Overview
Explore the profile of Michelle van der Vlugt-Daane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
331
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Deger T, Mendelaar P, Kraan J, Prager-van der Smissen W, van der Vlugt-Daane M, Bindels E, et al.
Mol Oncol
. 2021 Dec;
16(16):2981-3000.
PMID: 34964258
Intrapatient tumour heterogeneity is likely a major determinant of clinical outcome in cancer patients. To assess heterogeneity in a minimally invasive manner, methods to perform single circulating tumour cell (CTC)...
2.
Snaterse G, van Dessel L, van Riet J, Taylor A, van der Vlugt-Daane M, Hamberg P, et al.
JCI Insight
. 2021 May;
6(11).
PMID: 33974560
BACKGROUNDContinued androgen receptor (AR) signaling constitutes a key target for treatment in metastatic castration-resistant prostate cancer (CRPC). Studies have identified 11-ketotestosterone (11KT) as a potent AR agonist, but it is...
3.
Vitale S, Helmijr J, Gerritsen M, Coban H, van Dessel L, Beije N, et al.
BMC Cancer
. 2021 Mar;
21(1):315.
PMID: 33761899
Background: Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect...
4.
de Kruijff I, Sieuwerts A, Onstenk W, Kraan J, Smid M, Van M, et al.
Cancers (Basel)
. 2019 Aug;
11(8).
PMID: 31434336
(1) Background: Markers identifying which patients with metastatic, castration-resistant prostate cancer (mCRPC) will benefit from cabazitaxel therapy are currently lacking. Therefore, the aim of this study was to identify markers...
5.
Smid M, Wilting S, Uhr K, Rodriguez-Gonzalez F, de Weerd V, Prager-van der Smissen W, et al.
Genome Res
. 2019 Jan;
29(3):356-366.
PMID: 30692147
Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although their functional roles are debated. We analyzed RNA-seq data of 348 primary breast cancers and developed...
6.
van Dessel L, Vitale S, Helmijr J, Wilting S, van der Vlugt-Daane M, Oomen-de Hoop E, et al.
Mol Oncol
. 2018 Dec;
13(2):392-402.
PMID: 30516338
The emerging interest in circulating tumor DNA (ctDNA) analyses for clinical trials has necessitated the development of a high-throughput method for fast, reproducible, and efficient isolation of ctDNA. Currently, the...
7.
Smid M, Coebergh van den Braak R, van de Werken H, van Riet J, van Galen A, de Weerd V, et al.
BMC Bioinformatics
. 2018 Jun;
19(1):236.
PMID: 29929481
Background: Current normalization methods for RNA-sequencing data allow either for intersample comparison to identify differentially expressed (DE) genes or for intrasample comparison for the discovery and validation of gene signatures....
8.
Coebergh van den Braak R, Sieuwerts A, Lalmahomed Z, Smid M, Wilting S, Bril S, et al.
Sci Rep
. 2018 Mar;
8(1):5242.
PMID: 29588449
The identification of patients with high-risk stage II colon cancer who may benefit from adjuvant therapy may allow the clinical approach to be tailored for these patients based on an...
9.
Sieuwerts A, Mostert B, van der Vlugt-Daane M, Kraan J, Beaufort C, Van M, et al.
J Mol Diagn
. 2018 Feb;
20(3):316-325.
PMID: 29474983
Recent reports have emphasized the clinical relevance of detecting AR-V7 in circulating tumor cells (CTCs). Our aim was to set up a validated multicenter pipeline to measure AR-V7 by quantitative...
10.
Beije N, Sieuwerts A, Kraan J, Van N, Onstenk W, Vitale S, et al.
Mol Oncol
. 2017 Oct;
12(1):48-57.
PMID: 29063679
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge...